Full-Time

Device Development Lead

Associate Director

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$154.4k - $242.6k/yr

+ Short-term and long-term incentives + 401(k) company match

Lexington, MA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Quality Assurance (QA)
Risk Management

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A Bachelor of Science or Bachelor of Engineering degree in a relevant engineering or scientific area of study and a minimum of twelve years of relevant experience.
  • Relevant experience in device development and commercialization with demonstrated success leading cross-functional, global, or enterprise-wide programs in the biotechnology, pharmaceutical, or medical device industry.
  • End-to-end development experience with capital equipment.
  • Experience managing multiple complex cross-functional teams and processes to deliver key accountabilities.
  • Experience managing programs in different stages of development across many therapeutic areas.
  • Strong understanding of relevant regulatory frameworks governing devices across the product lifecycle.
  • Strong understanding of the business environment and relevant strategic, operational, and competitive drivers.
  • Excellent knowledge and application of device-related product development elements and relevant quality management systems.
  • Excellent knowledge and execution of subcontractor management and contract manufacturing organizations.
  • Strong understanding and competency in planning processes and decision-making.
  • Experience using standard program management tools and software, including integrated development plans, timelines, risk management, and budget development and monitoring.
  • Ability to translate strategies into tangible deliverables and manage and resolve complex strategic and operational issues and interactions between programs.
  • Ability to lead device program teams by building consensus within teams and Device Program Teams and Global Program Teams.
  • Ability to lead, motivate, and work effectively with cross-functional teams.
  • Knowledge of the medical device product development process and Food and Drug Administration and European Union Medical Device Regulation guidelines.
  • Familiarity with Microsoft Project and versatility in operations and program management tools to facilitate functional and geographic collaboration.
Responsibilities
  • The Device Development Lead is accountable for device program execution, translating product development strategy into clear and actionable plans and deliverables.
  • Work closely with Device Program Teams and drug Global Program Teams to align device strategy and execution.
  • Work with Device Project Managers to ensure proper planning and execution of project plans.
  • Lead cross-functional teams or multiple device teams through clinical development, product registration, and commercialization, including Life Cycle Management products requiring further development.
  • Create, manage, and execute device development project plans by building consensus within cross-functional teams.
  • Drive and manage the budgeting process for specific device development plans.
  • Monitor and manage overall program risk, communicate as appropriate, and provide risk mitigation solutions.
  • Report project status to Device Program Teams, Global Program Teams, and/or Product Development Team leadership committees.
  • Promote visibility and transparency of information within the device development team and across cross-functional teams.
  • Ensure device development activities align with Takeda’s Stage Gate Milestone framework and support Design Transfer readiness.
  • Lead and drive development and execution of Target Device Profile and drug Target Product Profile alignment.
  • Develop and lead high-performing device development cross-functional teams.
  • Drive budgeting and ensure adequate resource deployment, including operating expenditure, capital expenditure, and full-time equivalent resources, in support of approved integrated device development plans.
  • Represent the Device Development team at product governance bodies, including Global Program Teams and Product Development Teams.
  • Facilitate preparations and analyses for device-related business reviews, scenario planning, routine evaluation processes, and progress against strategy and action plans.
  • Collaborate with Global Program Teams and other cross-functional governance bodies to evaluate device-related product and program opportunities and develop integrated execution plans.
  • Provide direction on device program requirements in alignment with the Product/Device operating model to meet external customer and business stakeholder expectations.
  • Collaborate with global commercial teams to align device strategy with market needs and launch readiness.
  • Support digital health initiatives by integrating connected-care capabilities into device development plans as needed.
  • Oversee quality assurance activities and ensure compliance with internal standard operating procedures and external regulatory standards.
  • Manage multiple program teams as needed while maintaining a high-level view of program impact on Global Program Teams, Device Program Teams, and organizational strategy.
  • Build and maintain relationships with internal and external partner organizations, including contract research and development and manufacturing organizations, device original equipment manufacturer suppliers, Global Product Leads, Clinical Science, Clinical Operations, Quality Assurance, Procurement, Business Development, Research, and brand teams.
  • Facilitate execution of the global device program strategy.
  • Lead and drive development and execution of strategic device plans, Long Range Plans, Life Cycle Management Plans, and geographic expansion plans aligned with program strategy.
Desired Qualifications
  • Strong knowledge and understanding of global device product development and commercialization in the pharmaceutical industry.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Orzeyful launch opens a new neurology franchise with disease-modifying pricing power.
  • Takeda’s Q1 fiscal 2026 revenue rose 10.2% reported, driven by new launches.
  • Boltz partnership gives Takeda organization-wide AI access for structure prediction and generative design.

What critics are saying

  • Boston jurors found Takeda liable on May 18, 2026; appeal runs through 2026.
  • Takeda booked roughly 403.5 billion yen for Amitiza exposure, crushing fiscal 2025 profit.
  • Takeda will cut about 4,500 jobs in fiscal 2026, signaling integration strain after Shire.

What makes Takeda unique

  • Takeda’s Orzeyful became the first FDA-approved orexin therapy on August 5, 2026.
  • Takeda already won China approval for Orzeyful in July 2026, extending first-mover advantage.
  • Takeda’s dengue vaccine is India’s first approved Japanese dengue vaccine, strengthening emerging-market positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.

Yahoo Finance
Jul 30th, 2026
Takeda Pharmaceutical Q1 results on track as new launches offset mature product declines

Takeda Pharmaceutical reported first-quarter fiscal 2026 results aligned with its full-year outlook. Revenue totalled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis but down 0.5% at constant exchange rates. Core operating profit reached JPY 358.9 billion, rising 11.5% on an actual FX basis. The company's core inline brands, representing 58% of total revenue, grew 2.3% at constant exchange rates. New launches accounted for 4% of revenue but grew 22.6%, supported by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA. Takeda is preparing three product launches: ORZEYFUL for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. The company maintained its fiscal 2026 guidance and expects to generate JPY 650 billion to JPY 750 billion in free cash flow.

Nikkei Asia
Jul 21st, 2026
India approves first dengue vaccine from Japan's Takeda

India has approved Takeda Pharmaceutical's dengue vaccine, marking the country's first approved vaccine for the disease. The Japanese drugmaker received regulatory approval as authorities seek to combat dengue's accelerating transmission across India. Dengue, a mosquito-borne viral infection, poses a significant public health challenge in tropical regions. The approval represents a milestone in India's efforts to address the disease burden. The vaccine's introduction comes as dengue cases continue to rise in the country, making prevention efforts increasingly urgent for Indian health authorities.

Business Wire
Jun 24th, 2026
Julie Kim becomes Takeda's president and CEO as pharmaceutical giant prepares three major launches

Takeda has appointed Julie Kim as Representative Director, President and CEO, completing an 18-month transition. Shareholders elected Kim as an internal director during the company's 150th Annual General Meeting in Osaka, after which the Board appointed her to the top role. Former president and CEO Christophe Weber retired following the meeting. Kim joined Takeda in 2019 through the Shire acquisition and previously held roles including president of the Plasma-Derived Therapies Business Unit and president of the U.S. Business Unit. She brings over three decades of global healthcare experience. Shareholders also elected three new external directors: Bruce Broussard, Koichiro Kimura and Dr Paul Stoffels. Takeda's Board now comprises 11 members, with eight serving as external directors. The company plans three major launches over the next 12 months.